Snowbird Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2001



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Gene Therapy 2001: A Gene Odyssey (A1)


Organizer(s) Mark A. Kay and Donald B. Kohn
January 6—11, 2001
Snowbird Resort • Snowbird, Utah USA
Abstract Deadline: Sep 6, 2000
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Nov 6, 2000

Summary of Meeting:
Gene therapy approaches have made important strides in the last several years, in large part due to the technical advances in vector delivery approaches. Pre-clinical studies have demonstrated that new vector designs yield more persistent gene expression and reduced toxicity, leading to prolonged and therapeutic levels of clinically relevant gene products in many important cell targets. These advances are likely to lead to success in ongoing clinical trials. However, many problems have not been solved, and some diseases with inaccessible target cells or complex pathophysiology remain recalcitrant to effective gene therapy with current approaches. Moreover, there are reasonable safety concerns that need to be addressed before less severe medical conditions can be considered for gene therapy. The meeting will highlight recent successes and remaining barriers that still challenge the gene therapy community as it relates to basic science, pre-clinical animal studies, and clinical trials.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SATURDAY, JANUARY 6

14:00—19:00
Registration

Ballroom Lobby 3
18:15—19:15
Welcome

Golden Cliff
19:15—19:30
Orientation

Ballroom 3
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Ballroom 3
Savio L.C. Woo, Mount Sinai School of Medicine, USA
Gene Therapy: Current Events and Future Challenges


SUNDAY, JANUARY 7

07:00—08:00
Breakfast

Superior/Wasatch
08:00—11:30
Viral Vectors
Meeting has ended...abstracts no longer viewable online.

Ballroom 3
* Joseph C. Glorioso III, University of Pittsburgh School of Medicine, USA
Application of HSV Gene Vectors to Nervous System Disease

Olivier Danos, REGENXBIO Inc, USA
Factors Influencing AAV-Mediated Gene Transfer in vivo

Jeffrey S. Chamberlain, University of Washington, USA
Adenoviral Vectors for Gene Transfer to Muscle

R. Jude Samulski, University of North Carolina at Chapel Hill, USA
AAV Vectors, Pros and Con

James M. Wilson, University of Pennsylvania, USA
Innate and Acquired Immunity to Vectors

09:00—09:20
Coffee Break

Ballroom Lobby
11:30—13:00
Poster Setup

Ballroom 2
16:00—18:00
POSTER SESSION 1: Viral Vectors/Late Breaking Developments

Ballroom 2
17:00—18:00
Social Hour

Ballroom Lobby
20:00—21:30
Coffee Available

Ballroom Lobby
20:00—22:00
Late Breaking Developments - Short Talks Chosen from Abstracts
Meeting has ended...abstracts no longer viewable online.

Ballroom 3
* Mark A. Kay, Stanford University, USA

Wenfang Shi, Ohio State University/Children's Research Institute, USA
Mutational Analysis of Adeno-Associated Virus (AAV) Capsid Protein Genes and Development of Receptor-Targeted AAV Vectors

Scott D. Boden, Emory University, USA
Adenoviral Delivery of LIM Mineralization Protein-1 Successfully Induces Lumbar Spine Fusion

Clare Thomas, Nature Publishing Group, UK
Increased Stability of High-Capacity Adenovirus-Mediated Transgene Expression in the Brains of Immunized Animals

Thomas J. Wickham, Rubius Therapeutics, USA
Genetically Targeting Adenovirus Vectors

John C. Kappes, University of Alabama, Birmingham, USA
Transduction of Hematopoietic Stem Cells using a Trans-Lentiviral Vector that Affords Predictable Safety

Andreas Huser, HepaVec AG, Germany
Envelope Modification of Baculovirus: Complement Resistant and Targeted Gene Transfer Vectors

Dan Gazit, Hebrew University, Cedars Sinai Medical Center, USA
Bone Stem Cell Mediated Gene Therapy and Tissue Engineering


MONDAY, JANUARY 8

07:00—08:00
Breakfast

Superior/Wasatch
08:00—11:00
Emerging Technologies. Session Sponsored by The March of Dimes Birth Defects Foundation.
Meeting has ended...abstracts no longer viewable online.

Ballroom 3
* David W. Russell, University of Washington, USA
Homologous Gene Targeting by AAV Vectors

Alfred S. Lewin, University of Florida, USA
AAV-Vectored Ribozymes as Therapy for Dominantly Inherited Disease

Gerald F. Joyce, The Salk Institute, USA
DNA Enzymes

David M. Spencer, Bellicum Pharmaceuticals, USA
Synthetic Regulation of Apoptosis for Gene Therapy: The Last Casp

Victor M. Rivera, ARIAD Pharmaceuticals Inc., USA
Regulated Delivery of Secreted Proteins

09:00—09:20
Coffee Break

Ballroom Lobby
11:00—13:00
Poster Setup

Ballroom 2
16:00—18:00
POSTER SESSION 2: Emerging Technologies/Non Viral Vectors

Ballroom 2
17:00—18:00
Social Hour

Ballroom Lobby
20:00—21:30
Coffee Available

Ballroom Lobby
20:00—22:20
Non Viral Vectors. Session Sponsored in part by Valentis, Inc.
Meeting has ended...abstracts no longer viewable online.

Ballroom 3
* Jon A. Wolff, Roche Madison, USA
Natural IgM Antibodies in Normal Serum Selectively Recognize Protein Carboxy-Terminal Sequences

Francis C. Szoka Jr., University of California, San Francisco, USA
Improving Catonic Lipid Gene Transfer Through Chemistry

Clifford J. Steer, University of Minnesota Medical School, USA
Gene Repair - A Viable Alternative Gene Therapy

Mark E. Davis, California Institute of Technology, USA
Design and Synthesis of Cyclodextrin-Containing Polymers for Systemic Gene Delivery


TUESDAY, JANUARY 9

07:00—08:00
Breakfast

Superior/Wasatch
08:00—11:00
Preclinical/Clinical Trials I. Session Sponsored by Avigen Inc.
Meeting has ended...abstracts no longer viewable online.

Ballroom 3
Mark A. Kay, Stanford University, USA
Liver-Based Gene Therapy for Genetic Diseases

* Katherine A. High, Spark Therapeutics, USA
Preclinical and Clinical Studies of AAV-Mediated Gene Transfer for Hemophilia

Lawrence C. Chan, Baylor College of Medicine, USA
Helper-Dependent Adenoviral Vectors for the Treatment of Dyslipidemia - Preclinical Studies

Christine L. Halbert, Fred Hutchinson Cancer Research Center, USA
Progress in Gene Therapy for Cystic Fibrosis Using AAV Vectors

09:00—09:20
Coffee Break

Ballroom Lobby
11:00—13:00
Poster Setup

Ballroom 2
16:00—18:00
POSTER SESSION 3: Preclinical/Clinical Trials/Stem Cells/Cancer

Ballroom 2
17:00—18:00
Social Hour

Ballroom Lobby
20:00—21:30
Coffee Available

Ballroom Lobby
20:00—22:00
Preclinical/Clinical Trials II
Meeting has ended...abstracts no longer viewable online.

Ballroom 3
* Helen M. Blau, Stanford University, USA
Angiogenesis

Victor J. Dzau, Duke University Medical Center, USA
Gene Therapy Strategy for Coronary Heart Disease

Paul A. Khavari, Stanford University, USA
Progress in Therapeutic Gene Transfer to Skin


WEDNESDAY, JANUARY 10

07:00—08:00
Breakfast

Superior/Wasatch
08:00—11:30
Stem Cells
Meeting has ended...abstracts no longer viewable online.

Ballroom 3
* Markus Grompe, Oregon Health & Science University, USA
Extrahepatic Stem Cells and Their Therapeutic Application

Evan Snyder, Sanford-Burnham Medical Research Institute, USA
Neural Stem Cells May be Ideally Suited for Gene Therapy and Cell Replacement in the Degenerating CNS

Gay M. Crooks, University of California, Los Angeles, USA
Characterization and Transduction of Human Lympho-Hematopoietic Stem Cells

Robert J. Deans, BlueRock Therapeutics, USA
Mesenchymal Stem Cells: Cell and Gene Therapy Applications

Richard C. Mulligan, Children's Hospital Boston, USA
Stem Cell Plasticity: Implications for Cell and Gene Therapy

09:00—09:20
Coffee Break

Ballroom Lobby
15:00—16:00
Coffee Available

Ballroom Lobby
16:00—17:30
Cancer
Meeting has ended...abstracts no longer viewable online.

Ballroom 3
Frank McCormick, University of California, San Francisco, USA
Adenoviruses with Host Ranges Restricted to Cancer Cells

Eli Gilboa, University of Miami, Miller School of Medicine, USA
Tumor RNA Transfected Dendritic Cells: From Vaccination to Antigen Discovery

* Ken Cornetta, Indiana University, USA
Drug Resistance Genes into Hematopoietic Cells

19:00—20:00
Social Hour

Ballroom Lobby
20:00—22:00
Banquet

Ballroom 2 - 3
21:00—00:00
Entertainment

Ballroom 2 - 3

THURSDAY, JANUARY 11

 
Departure


*Session Chair †Invited, not yet responded.



We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676